日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A sensitive and specific assay to characterize plasma kallikrein activity in plasma from patients with hereditary angioedema

一种灵敏且特异的检测方法,用于表征遗传性血管性水肿患者血浆中的激肽释放酶活性。

Lee, Daniel K; Ghannam, Arije; Murugesan, Nivetha; Vincent, Denis; Dona, Micaela; Cohn, Danny M; Adatia, Adil; Smith, Michael D; Audhya, Paul K; Hampton, Sally L; Feener, Edward P

A mechanism for hereditary angioedema caused by a methionine-379-to-lysine substitution in kininogens

激肽原中甲硫氨酸-379 被赖氨酸取代引起的遗传性血管性水肿的机制

Dickeson, S Kent; Kumar, Sunil; Sun, Mao-Fu; Litvak, Maxim; He, Tracey Z; Phillips, Dennis R; Roberts, Elijah T; Feener, Edward P; Law, Ruby H P; Gailani, David

A randomized double-blinded trial to assess recurrence of systemic allergic reactions following COVID-19 mRNA vaccination

一项随机双盲试验旨在评估接种 COVID-19 mRNA 疫苗后全身性过敏反应的复发情况。

Khalid, Muhammad B; Zektser, Ellen; Chu, Eric; Li, Min; Utoh, Joanna; Ryan, Patrick; Loving, Hanna S; Harb, Roa; Kattappuram, Robbie; Chatman, Lindsay; Hartono, Stella; Claudio-Etienne, Estefania; Sun, Guangping; Feener, Edward P; Li, Zhongbo; Lai, Samuel K; Le, Quang; Schwartz, Lawrence B; Lyons, Jonathan J; Komarow, Hirsh; Zhou, Zhao-Hua; Raza, Haniya; Pao, Maryland; Laky, Karen; Holland, Steven M; Brittain, Erica; Frischmeyer-Guerrerio, Pamela A

Rationale of Basic and Cellular Mechanisms Considered in Updating the Staging System for Diabetic Retinal Disease

更新糖尿病视网膜疾病分期系统所考虑的基本和细胞机制的理论依据

Hartnett, M Elizabeth; Fickweiler, Ward; Adamis, Anthony P; Brownlee, Michael; Das, Arup; Duh, Elia J; Feener, Edward P; King, George; Kowluru, Renu; Luhmann, Ulrich F O; Storti, Federica; Wykoff, Charles C; Aiello, Lloyd Paul

Titanium is a potent inducer of contact activation: implications for intravascular devices

钛是接触激活的强效诱导剂:对血管内装置的意义

Litvak, Maxim; Shamanaev, Aleksandr; Zalawadiya, Sandip; Matafonov, Anton; Kobrin, Anton; Feener, Edward P; Wallisch, Michael; Tucker, Erik I; McCarty, Owen J T; Gailani, David

Oral FXIIa inhibitor KV998086 suppresses FXIIa and single chain FXII mediated kallikrein kinin system activation

口服 FXIIa 抑制剂 KV998086 可抑制 FXIIa 和单链 FXII 介导的激肽释放酶激肽系统激活

Allen C Clermont #, Nivetha Murugesan #, Hannah J Edwards, Daniel K Lee, Natasha P Bayliss, Edward J Duckworth, Stephen J Pethen, Sally L Hampton, David Gailani, Edward P Feener

A mechanism for hereditary angioedema caused by a lysine 311-to-glutamic acid substitution in plasminogen

纤溶酶原中赖氨酸 311 位点被谷氨酸取代引起的遗传性血管性水肿的机制

S Kent Dickeson, Sunil Kumar, Mao-Fu Sun, Bassem M Mohammed, Dennis R Phillips, James C Whisstock, Adam J Quek, Edward P Feener, Ruby H P Law, David Gailani

Pharmacological suppression of the kallikrein kinin system with KVD900: An orally available plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema

KVD900是一种口服的血浆激肽释放酶抑制剂,可用于按需治疗遗传性血管性水肿,其通过药理学手段抑制激肽释放酶-激肽系统。

Duckworth, Edward J; Murugesan, Nivetha; Li, Lily; Rushbrooke, Louise J; Lee, Daniel K; De Donatis, Gian Marco; Maetzel, Andreas; Yea, Christopher M; Hampton, Sally L; Feener, Edward P

Plasma Kallikrein Contributes to Intracerebral Hemorrhage and Hypertension in Stroke-Prone Spontaneously Hypertensive Rats

血浆激肽释放酶导致易患中风的自发性高血压大鼠发生脑出血和高血压

Jian Guan #, Allen C Clermont #, Loc-Duyen Pham, Tuna Ustunkaya, Alexey S Revenko, A Robert MacLeod, Edward P Feener, Fabrício Simão

Continuous genomic diversification of long polynucleotide fragments drives the emergence of new SARS-CoV-2 variants of concern

长链多核苷酸片段的持续基因组多样化驱动了令人担忧的SARS-CoV-2新变种的出现。

Murugadoss, Karthik; Niesen, Michiel J M; Raghunathan, Bharathwaj; Lenehan, Patrick J; Ghosh, Pritha; Feener, Tyler; Anand, Praveen; Simsek, Safak; Suratekar, Rohit; Hughes, Travis K; Soundararajan, Venky